.Pharmacolibrary.Drugs.P_AntiparasiticProductsInsecticidesAndRepellents.P01B_Antimalarials.P01BF02_ArtesunateAndMefloquine.ArtesunateAndMefloquine

Information

Artesunate and mefloquine is a fixed-dose combination antimalarial therapy used for the treatment of uncomplicated Plasmodium falciparum malaria. Artesunate is a fast-acting artemisinin derivative, while mefloquine is a longer-acting antimalarial agent. This combination is approved and widely used in endemic regions as a standard therapy for malaria.

Pharmacokinetics

Pharmacokinetic parameters for artesunate and mefloquine in healthy adult subjects, mostly from Southeast Asia, following oral administration of the fixed-dose combination.

References

1. Rattanapunya, S, et al., & Na-Bangchang, K (2015). Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults. Malaria journal 14 400–None. DOI:10.1186/s12936-015-0916-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26452725

2. Reuter, SE, et al., & Olliaro, PL (2015). Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria. The Journal of antimicrobial chemotherapy 70(3) 868–876. DOI:10.1093/jac/dku430 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25377567

3. Birgersson, S, et al., & Tarning, J (2019). Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with uncomplicated . Wellcome open research 4 45–None. DOI:10.12688/wellcomeopenres.14849.2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32025570

Revisions

• 06/2025 initial generated model